Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 214   

Articles published

MRK 56.29 +0.32 (0.57%)
price chart
Merck & Company Inc. (new) (MRK) Closes 0.54% Up on the Day for February 16
Shares of Merck & Company Inc. (new) (MRK) ended the trading day Friday at $56.29, representing a move of 0.54%, or $0.3 per share, on volume of 11.61 million shares.
Janney Capital Management LLC Sells 936 Shares of Merck & Co., Inc ...  The Ledger Gazette
Zacks: Brokerages Anticipate Merck & Co., Inc. (MRK) Will Post Quarterly ...  StockNewsTimes
Another Alzheimer's flop as Merck pulls promising late-stage drug trial after ...
The most promising clinical trial for an Alzheimer's drug has been pulled as a review showed it is unlikely to work. Merck & Co Inc was widely tipped to be a frontrunner in the global race to find a treatment for the incurable neurodegenerative disease ...
Merck (MRK) Halts Another Late Stage Study on Alzheimer's  Nasdaq
Merck & Company Inc. (new) (MRK) Closes 1.99% Up on the Day for February 15
Shares of Merck & Company Inc. (new) (MRK) ended the trading day Thursday at $55.99, representing a move of 1.99%, or $1.09 per share, on volume of 10.07 million shares.
How Does Merck & Co., Inc. (MRK) Stack Up Right Now?  StockNewsJournal
How Much Potential There Is For Merck & Co., Inc. (MRK), Trevena, Inc ...  Post Analyst
Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict
Merck sells its own hepatitis C drug, Zepatier. The company won a $200 million jury verdict last March in a separate patent infringement case against Gilead over hepatitis C drugs.
The Future of Merck & Co., Inc. Stock Is With Keytruda
Merck & Co., Inc. (NYSE:MRK) mustered an earnings beat for its fourth quarter, which - despite falling short of revenue estimates - was enough to sate shareholders.
Analyst Activity – Credit Suisse Group Lowers Its Price Target On Merck & ...  Market Exclusive
Merck & Company Inc. (new) (MRK) Closes 0.96% Down on the Day for February 13
Shares of Merck & Company Inc. (new) (MRK) ended the trading day Tuesday at $54.90, representing a move of -0.96%, or $0.53 per share, on volume of 17 million shares.
Is Momentum Shifting? – Merck & Co., Inc. (MRK), Teck Resources Limited ...  Post Analyst
Merck & Co Inc. Announces Advance In Q4 Profit
(RTTNews.com) - Merck & Co Inc. ( MRK ) revealed a profit for its fourth quarter that gained ground from last year. The company said its bottom line advanced to $2.67 billion, or $0.98 per share.
Merck: Keytruda Remains Key
As a testament to the long-term success, investors who bought shares about three decades ago now receive an annual dividend payment being equal to this purchase price back in the day.
Merck & Co., Inc.'s Rally Could Burn Investors
The New Year has been good to Merck & Co., Inc. (NYSE:MRK), as shares of the global giant rallied to their best level since October on the back of positive headlines this week.
Is It Too Late To Buy Merck & Co Inc (NYSE:MRK)?  Simply Wall St
Merck & Company Inc. (new) (MRK) Closes 0.25% Up on the Day for January 19  Equities.com
Lookout for Price Target? Merck & Co., Inc. (MRK), Comcast Corporation (CMCSA)
ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.